OptimizeRx (OPRX) 8-K Changes in Registrant's Certifying Accountant

Exhibit 16.1

 

April 25, 2019

U.S. Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, N.W.

Washington, D.C. 20549-7561

Re: OptimizeRx Corporation

Dear Sir or Madam:

We have read the statements of OptimizeRx Corporation relating to the events described under Item 4.01 of Form 8-K dated April 22, 2019 and we agree with such statements as they pertain to our Firm.

Sincerely,

/s/ Sadler, Gibb & Associates, LLC

Sadler, Gibb & Associates, LLC